Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
House conservatives to lead prayer for end to...
GOP senators push for Charlie Kirk statue in...
Biden autopen investigation ‘has heated up’ as DOJ...
States sue Trump admin over billions in looming...
NASA’s ‘quiet’ supersonic jet completes first flight in...
Trump claims Asia tour returned ‘trillions’ to US...
‘Unprecedented’ panel of federal judges will tackle antisemitism...
Schumer, Dems call ‘bull—-‘ on Trump administration over...
US rescue teams to descend on hard-hit Caribbean...
Republicans dub Fetterman ‘voice of reason’ after he...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by admin November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS

previous post
HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States
next post
Stop funding the woke and the stupid

You may also like

President Trump gave me back my life after...

April 30, 2025

‘Nothing to stand on’: Ex-White House physician slams...

July 11, 2025

Trump’s final Cabinet pick, Mike Waltz, confirmed by...

September 20, 2025

Ukraine: How the war shifted in 2024

December 31, 2024

White House yet to release visitor logs for...

November 20, 2024

Elon Musk scraps with Chuck Schumer, suggesting the...

April 9, 2025

Iran denies involvement in Trump assassination plot outlined...

November 9, 2024

‘Due to overhelming support:’ Turning Point USA says...

September 22, 2025

Trump blasts Massie as ‘the worst Republican Congressman’...

July 22, 2025

Jordan demands Jack Smith testify over ‘partisan and...

October 14, 2025

Recent Posts

  • House conservatives to lead prayer for end to political violence, government shutdown
  • GOP senators push for Charlie Kirk statue in Trump’s National Garden of American Heroes
  • Biden autopen investigation ‘has heated up’ as DOJ looks at Delaware, DC: source
  • States sue Trump admin over billions in looming cuts to SNAP, food stamps
  • NASA’s ‘quiet’ supersonic jet completes first flight in potential breakthrough for commercial air travel

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (946)
    • Investing (3,304)
    • Politics (4,045)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.